Rebecca Araujo

DocwireNews

Each week on DocWire News, editors bring you the latest in oncology news and cancer research. In case you missed it, here are this week&rsquo;s top headlines:Keep reading for the breakdown on these top stories.<ul>
<li>VIDEO: <a href="https://www.docwirenews.com/docwire-pick/dr-catherine-shu-discusses-a-study-with-important-implications-in-the-treatment-of-lung-cancer/">Dr. Catherine Shu on CHRYSALIS-2: Amivantamab Regimen in Relapsed NSCLC </a></li>
<li><a href="https://www.docwirenews.com/urban-health-today/urban-health-picks/lung-cancer-screening-do-updated-criteria-address-racial-disparities/">Lung Cancer Screening: Do Updated Criteria Address Racial Disparities?</a></li>
<li><a href="https://www.docwirenews.com/vte-knowledge-hub/vte-knowledge-hub-picks/cost-effectiveness-of-apixaban-for-venous-thrombosis-prophylaxis-in-patients-with-cancer/">Cost-Effectiveness of Apixaban for Venous Thrombosis Prophylaxis in Patients with Cancer</a></li>
</ul>RELATED: Last Week&rsquo;s Round-Up: <a href="https://www.docwirenews.com/weekly-roundup/oncology-news-round-up-detecting-high-risk-hpv-new-ebrt-guidelines/">Detecting High-Risk HPV; New EBRT Guidelines</a><h2>Dr. Catherine Shu: Amivantamab Regimen in Relapsed NSCLC</h2>Editors spoke with Catherine Shu, MD, <a href="https://www.cancer.columbia.edu/profile/catherine-shu-md">medical oncologist</a> and Clinical Director of the Thoracic Medical Oncology Group at Columbia University Herbing Irving Comprehensive Medical Center, about findings from Janssen&rsquo;s CHRYSALIS-2 study, which demonstrated the efficacy of amivantamab in combination with lazertinib in the treatment of patients with relapsed non-small cell lung cancer (NSCLC).This study included patients who had progressed after treatment with osimertinib followed by platinum chemotherapy. In this population of patients with relapsed NSCLC, the response rate to amivantamab plus lazertinib was 41% overall, with 69% of respondents achieving a clinical benefit.Additionally, the amivantamab combination was well-tolerated. According to Dr. Shu, side effects included rash, paronychia, stomatitis, and mouth sores. Some patients experienced infusion-related reactions, typically on the first day of infusion, such as increased blood pressure, flushing, chest pain, and shortness of breath. These effects were manageable, according to Dr. Shu. &ldquo;It&rsquo;s typically within the first few minutes of the infusion. We stop the infusion, we slow down the rate, we give them additional medications, and then most people are able to get through it,&rdquo; she said.https://www.docwirenews.com/docwire-pick/dr-catherine-shu-discusses-a-study-with-important-implications-in-the-treatment-of-lung-cancer/RELATED: <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/depression-may-worsen-survival-in-advanced-non-small-cell-lung-cancer/">Depression May Worsen Survival in Advanced Non-Small Cell Lung Cancer</a><h2>Increased Eligibility with Updated Lung Cancer Screening</h2>The 2021 lung cancer screening criteria from the <a href="https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening">U.S. Preventative Services Task Force (USPSTF)</a> was found to reduce racial disparities in eligibility for screening compared to the 2013 version of this guideline, according to a study published in JAMA Oncology.The 2021 USPSTF criteria demonstrated comparable eligibility rates regardless of race (65% of White patients vs. 63% of African American patients). This rate was a significant improvement from the 2013 criteria (52% of White patients vs. 42% of African American patients).However, a prediction-model based screening criteria (the 2012 Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial model) demonstrated higher sensitivity and specificity compared with the 2021 criteria.https://www.docwirenews.com/urban-health-today/urban-health-picks/lung-cancer-screening-do-updated-criteria-address-racial-disparities/RELATED: <a href="https://www.docwirenews.com/hematology-oncology/improving-diversity-in-smoking-cessation-trials/">Improving Diversity in Smoking Cessation Trials</a><h2>Cost Analysis of Apixaban for VTE Prophylaxis</h2>Researchers from the University of Ottawa evaluated the cost-utility of apixaban for venous thromboembolism (VTE) prophylaxis in patients with cancer compared to standard care, which does not include any primary thromboprophylaxis. Their findings, published in the Canadian Medical Association Journal, established that apixaban was a cost-saving option for VTE prophylaxis in ambulatory patients with cancer at intermediate-to-high risk of VTE who were starting chemotherapy.Across a lifetime horizon, apixaban resulted in a lower cost for the health system (Can$7902.98 vs. Can$14875.82) and an improvement in quality of life years (QALYs; 9.089 vs. 9.0006) versus standard care. The primary contributor to the cost-effectiveness of apixaban was the relative risk of VTE. Further analysis demonstrated that a willingness to pay Can$50,000 per QALY with apixaban yielded the highest probability (99.87%) of being the most cost-effective for the health system.https://www.docwirenews.com/vte-knowledge-hub/vte-knowledge-hub-picks/cost-effectiveness-of-apixaban-for-venous-thrombosis-prophylaxis-in-patients-with-cancer/<h2>Want to see more oncology news?</h2>Check out last week&rsquo;s <a href="https://www.docwirenews.com/weekly-roundup/oncology-news-round-up-detecting-high-risk-hpv-new-ebrt-guidelines/">Round-Up</a>, and be sure to keep up with the latest oncology news and cancer research here on DocWire, updated daily!

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Latest News

Oncology News Round-Up: Amivantamab in Relapsed NSCLC, and More

Oncology

Each week on DocWire News, editors bring you the latest in oncology news and cancer research. In case you missed it, here are this week’s top headlines:
 ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe